Cardiology Xagena
The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared Alirocumab ( Praluent ) with placebo, added to high-inte ...
Inhibition of the P2Y12 receptor by an oral P2Y12 inhibitor with loading doses along with cyclooxygenase-1 inhibition by Aspirin Acetylsalicylic acid ) is considered a first-line treatment strategy in ...
Thiazide, a first-line therapy for hypertension, lowers blood pressure, increases bone mineral density, and reduces the risk of fractures. However, hyponatremia, an adverse effect of thiazide, is as ...
In pulmonary arterial hypertension ( PAH ), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapie ...
The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction ( LVD ) after acute m ...
The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs ), compared with use of angiotensin receptor blockers, is associated wit ...
HeartMate 3 Left Ventricular Assist Device ( LVAD ) has received U.S. Food and Drug Administration ( FDA ) clearance as a destination therapy for people living with advanced heart failure. With th ...
In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and mortality. However, several important presentation characte ...
In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein cholesterol ( LDL-C ) reduction. Researchers have assessed wh ...
A study has evaluated the influence of anemia on long-term outcomes of patients with acute coronary syndrome undergoing percutaneous coronary intervention ( PCI ). The study included 5668 consecuti ...
The SWEDEHEART ( Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies ) registry routinely collects information on pa ...
Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany ) has shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safe ...
Previous studies have shown that low socioeconomic status is associated with a first myocardial infarction, but these findings could not be extended to heart attack survivors to calculate their risk o ...
Mineralocorticoid receptor antagonists ( MRAs ) have been demonstrated to improve outcomes in reduced ejection fraction heart failure ( HFrEF ) patients. However, MRAs added to conventional treatmen ...
Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree t ...
